Terminated PHASE2 INTERVENTIONAL 1-arm NCT03683277

IPD in RRMM Characterized with Genomic Abnormalities of Adverse Prognostic (IFM2014-01)

Multicenter Open Label Phase 2 Single Arm Study of Ixazomib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Characterized with Genomic Abnormalities of Adverse Adverse Prognostic

Sponsor: AXONAL

Conditions Genetic Condition Multiple Myeloma Relapsed and Refractory Multiple Myeloma

Interventions Ixazomib/Pomalidomide/Dexamethasone

Updated 8 times since 2018 Last updated: Feb 17, 2025 Started: Nov 3, 2019 Primary completion: Dec 31, 2022 Completion: Feb 10, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Recruitment issue, 26 patients enrolled instead of 70 initially planned

This PHASE2 trial investigates Genetic Condition and Multiple Myeloma and is currently terminated or withdrawn. AXONAL leads this study, which shows 8 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Mar 2025 — Sep 2025 [monthly]

Terminated PHASE2
Sep 2024 — Mar 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jul 2023 — Jul 2024 [monthly]

Terminated PHASE2

Status: Not Yet Recruiting → Terminated

▶ Show 3 earlier versions

Oct 2021 — Jul 2023 [monthly]

Not Yet Recruiting PHASE2
Jan 2021 — Oct 2021 [monthly]

Not Yet Recruiting PHASE2
Oct 2018 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AXONAL
Bristol-Myers Squibb
Euraxi Pharma
Intergroupe Francophone du Myelome
Nantes University Hospital
QPS Holdings LLC
Takeda
University Hospital, Grenoble

Data source: Intergroupe Francophone du Myelome

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Angers, France , Avignon, France , Bayonne, France , Bobigny, France , Caen, France , Cesson-Sévigné, France , Créteil, France , Dijon, France , Dunkirk, France , Grenoble, France and 18 more locations